The role of glimepiride in the treatment of type 2 diabetes mellitus

Abstract

Importance of the field: Type 2 diabetes mellitus (T2DM) is increasingly prevalent throughout the world; controlling glycemia is an important part of preventing serious complications of diabetes. Sulfonylureas have been used in the treatment of type 2 diabetes for many years.

Areas covered in this review: This article reviews the pharmacological and clinical aspects of glimepiride, a second-generation sulfonylurea. Literature search was conducted in PubMed, and articles selected for relevance to pharmacology or clinical efficacy data from 1994 to 2009, with older references sought as indicated.

What the reader will gain: Pharmacology of glimepiride, data regarding clinical efficacy, key comparisons to other agents and emerging concepts related to glimepiride are discussed.

Take home message: Therapy with glimepiride improves the relative insulin secretory deficit found in T2DM, has antihyperglycemic efficacy equal to other secretagogues with reduced potential for hypoglycemia and may have additional actions contributing to glycemic control in T2DM.

Keywords::

• glimepiride
• hypoglycemia
• ischemic preconditioning
• sulfonylurea
• type 2 diabetes mellitus

Acknowledgements

We thank J Finkel for his assistance with graphic design and J Botts Hicks for her excellent editing skills.

Notes